Icatibant Piramal

Icatibant, the active ingredient in Icatibant Piramal, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema caused by C1‑inhibitor deficiency in patients of all ages.

GNH USA supplies Icatibant Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant sourcing for global markets.

Icatibant is used to manage hereditary angioedema by targeting the bradykinin pathway.

- Hereditary angioedema (C1‑inhibitor deficiency, type I): rapidly reduces swelling and pain during acute attacks. - Hereditary angioedema (type II): provides prompt symptom relief and shortens attack duration. - Hereditary angioedema (type III or idiopathic): effective in decreasing severity of swelling episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or airway: potentially life‑threatening swelling. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases. - Severe injection‑site necrosis: tissue death at the site of injection.

Before using Icatibant, consider the following safety measures.

- Contraindication: Do not use in patients with known hypersensitivity to icatibant or any excipients. - Pregnancy: Safety has not been established; use only if the potential benefit justifies the risk. - Breastfeeding: Caution advised; limited data are available. - Monitoring: Observe for signs of anaphylaxis or severe angioedema after injection. - Drug interactions: Review concomitant medications for potential bradykinin‑related effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence the bradykinin pathway or vascular tone.

Major Interactions (Avoid): - Concurrent use of other bradykinin B2 receptor antagonists: may lead to additive pharmacologic effects. - Simultaneous administration of C1‑esterase inhibitor concentrates: overlapping therapeutic action can increase risk of adverse events.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may reduce the effectiveness of icatibant by increasing bradykinin levels. - Angiotensin receptor blockers (ARBs): monitor blood pressure and swelling response. - Diuretics: watch for changes in fluid balance that could affect edema management.